查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466077

肺部疾病药物市场：按药物类别、按适应症、按药物类型、按分销管道、按最终用户分类 - 全球预测 2024-2030

Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年肺病治疗市场规模为793.5亿美元，预计2024年将达861.4亿美元，2030年将达1362.7亿美元，复合年增长率为8.03%。

肺部疾病治疗市场包括专为预防、诊断和治疗呼吸系统疾病而设计的各种治疗解决方案。肺部疾病药物主要用于治疗多种呼吸系统疾病，包括肺炎、结核病、气喘、慢性阻塞性肺病（COPD）、囊肿纤维化、过敏性鼻炎和其他肺部疾病。肺部疾病盛行率的上升以及政府促进疾病治疗的努力增加了对治疗肺部疾病的药物的需求。改善的报销政策和政府对肺病药物的有利核准也有助于市场成长。然而，产品召回事件可能会限制肺病药物的采用。与药物传递不足和抗药性发展相关的限制预计也将对采用治疗肺部疾病的药物构成挑战。此外，用于治疗肺部疾病的新生技药品和标靶药物的开发以及吸入药物输送疗法的进步预计将为市场提供潜在的成长机会。

主要市场统计
基准年[2023] 793.5亿美元
预测年份 [2024] 861.4亿美元
预测年份 [2030] 1362.7亿美元
复合年增长率（%） 8.03%

按药物类别：组合药物和单株抗体开发的进展使肺部疾病的个人化治疗成为可能

抗胆碱能药物是一类阻断乙酰胆碱作用的药物，乙酰胆碱是一种负责在气道中传递衝动的神经传导物质。这些药物透过减少支气管收缩和气道分泌物来发挥作用，可用于治疗慢性阻塞性肺病（COPD）和气喘。抗白三烯药物是一种透过阻断白三烯的作用来对抗呼吸系统发炎的药物，白三烯是参与免疫反应的化学物质，导致气道收缩和黏液产生。它主要用于治疗气喘，特别是对吸入性皮质类固醇和β2促效剂等常规治疗没有反应的患者。抗组织胺药物透过抑制组织胺（过敏反应过程中释放的化学信使）发挥作用，并减少过敏症状，如打喷嚏、搔痒和鼻塞。抗组织胺有助于治疗气喘和与过敏相关的慢性鼻炎，但主要针对肺部疾病。 Beta2促效剂是一种肺部疾病药物，可刺激支气管平滑肌细胞上的 β2 肾上腺素受体，引起支气管鬆弛和扩张，这对于控制气喘和慢性阻塞性肺病的症状至关重要。组合药物将两种或多种不同类别的药物结合起来，以提高疗效，同时最大限度地减少副作用。当单一疗法无法充分控制症状时，通常会开药。单株抗体是生物药品，旨在针对参与发炎和免疫介导的气道疾病（例如严重气喘）的特定细胞路径。口服和吸入的皮质类固醇是强效发炎药，用于治疗多种肺部疾病，如气喘和慢性阻塞性肺病。

需要有效的药物和用于治疗和管理 COPD 和囊肿纤维化的药物

过敏性鼻炎是一种因接触花粉、尘螨和动物皮屑等过敏原而影响鼻道的发炎疾病。最常用于治疗这种情况的药物包括抗组织胺、白三烯受体拮抗剂和鼻用皮质类固醇。支气管气喘是一种以气道阻塞和支气管痉挛为特征的慢性发炎呼吸道疾病。根据严重程度和患者个别需求，气喘治疗可能包括使用短效 β 受体促效剂(SABA)、长效 β 受体促效剂(LABA)、吸入性皮质类固醇 (ICS) 或生物製药。慢性阻塞性肺病（COPD）是一种与慢性支气管炎和肺气肿相关的肺部疾病，导致气流阻塞。囊肿纤维化是一种遗传性疾病，会导致肺部黏液积聚，导致慢性感染疾病和呼吸衰竭。主要治疗方法是用调节药物靶向有缺陷的囊肿纤维化跨膜电导调节蛋白（CFTR），并用支气管扩张剂、抗生素和粘液溶解剂控制症状。肺动脉高血压（PAH）是一种罕见严重的疾病，患者为肺部供血的动脉血压升高。用于治疗 PAH 的主要药物类别包括内皮素受体拮抗剂 (ERA)、前列腺环素类似物或促效剂、可溶性鸟苷酸环化酶刺激剂(sGCS) 和5 型磷酸二酯酶抑制剂( PDE-5i)。

药物类型 在肺部疾病管理中越来越偏好具有成本效益的学名药

处方药是需要医疗保健专业人员处方笺才能分发给患者的药物。这些药物在获得食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等政府机构核准之前，都会经过严格的测试和监管流程，以确保安全性和有效性。肺部处方药提供具有先进作用机制的标靶治疗，旨在解决呼吸系统疾病的根本原因。学名药在剂型、规格、给药途径、品质、性能特征和预期用途方面与品牌药在生物学上等效。这些药物在品牌药的专利到期后被引入市场，并且通常以低于品牌药的价格出售。成本效益是需要长期治疗的医疗保健提供者和无力负担费用的患者偏好学名药的一个主要因素。

分销管道：改善线上分销策略，提高产品在患者和医疗保健专业人员中的渗透率

医院药局是肺部药物的重要分销管道，主要是因为它们策略性地位置医疗机构内。这使得医护人员能够快速为患有慢性和急性呼吸道疾病的患者提供救命药物。网路药局已成为购买肺部疾病药物的便捷且经济高效的平台。网路药局提供到府外送、隐私、折扣等优势，无需去药局即可轻鬆取得药物。零售药局因其分布广泛且患者易于取得而成为肺部疾病药物的重要分销管道。

最终使用者：为医院的急性病例和严重呼吸道疾病提供多种速效药物。

在居家医疗领域，患有气喘、肺结核、慢性阻塞性肺病（COPD）等慢性呼吸系统疾病的患者需要定期用药和管理。医院是治疗呼吸系统疾病急性发作和重症病例的重要中心。专科诊所为患有特定呼吸系统疾病的患者提供服务，包括囊肿纤维化、间质性肺病和肺动脉高血压（PAH）。

区域洞察

由于该地区存在主要市场参与者，美洲地区拥有高度发展的肺科药物製造基础设施。在美国、加拿大、巴西等主要国家，慢性阻塞性肺病、结核病、气喘等呼吸道疾病在儿童和成人中流行，增加了对治疗肺部疾病药物的需求。德国、法国、义大利和西班牙等欧洲、中东和非洲国家由于人口老化，呼吸道疾病的盛行率也很高，促进了该地区的市场成长。沙乌地阿拉伯和阿拉伯联合大公国等中东国家正大力投资改善其卫生基础设施，以解决这个公共卫生问题。由于中国、印度和日本等主要国家政府投资的增加，亚洲地区的市场正在成长。该地区的市场相关人员专注于生产负担得起的肺部疾病学名药，并投资国内新药开拓。

FPNV定位矩阵

FPNV定位矩阵对于评估肺病药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对肺病药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.肺病治疗药物市场规模及预测是多少？

2.肺病药物市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3.肺病治疗药物市场的技术趋势与法规结构是什么？

4.肺病治疗药物市场主要厂商的市场占有率是多少？

5.进入肺病药物市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 努力解决肺部疾病的流行问题并促进疾病治疗和药物获取
      • 改善肺部疾病药物的报销并获得有利的政府核准
    • 抑制因素
      • 用于治疗肺部疾病的药物召回增加
    • 机会
      • 开发治疗肺部疾病的新型生物製药和标靶药物
      • 吸入药物传递疗法和技术的进展
    • 任务
      • 与不适当的药物传递和抗药性发展相关的限制
  • 市场区隔分析
    • 药物类别：合併药物和单株抗体製剂的进展，为肺部疾病提供个人化治疗
    • 适应症：需要有效的药物来治疗和管理慢性阻塞性肺病和囊肿纤维化
    • 药物类型：治疗肺部疾病的趋势有利于具有成本效益的学名药
    • 分销管道：改善线上分销策略，提高产品在患者和医疗保健提供者中的渗透率
    • 最终使用者：提供各种速效药物来治疗医院的急性病例和严重呼吸道疾病。
  • 市场趋势分析
    • 由于呼吸系统疾病盛行率上升以及主要市场参与者开发用于疾病管理的创新肺部疾病治疗方法，预计美洲将显着增长。
    • 亚太地区创新肺病治疗药物共同生产的既定空间得到了政府对药物商业化的财政支持的大力支持。
    • 改善的医疗基础设施和政府支援将重点放在研发以满足欧洲、中东和非洲地区肺病药物的需求
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章依药物类别分類的肺部疾病治疗药物市场

  • 抗胆碱能药
  • 抗白三烯
  • 抗组织胺药
  • β2促效剂
  • 伴随药物
  • 单株抗体
  • 口服和吸入性皮质类固醇

第七章依适应症分類的肺部疾病治疗药物市场

  • 过敏性鼻炎
  • 气喘
  • 慢性阻塞性肺病
  • 囊肿纤维化
  • 肺动脉高血压

第八章依药品类型分類的肺部疾病治疗药品市场

  • 学名药
  • 处方药

第九章肺部疾病治疗药物市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第十章肺部疾病治疗药物市场：依最终使用者分类

  • 居家护理
  • 医院
  • 专科诊所

第十一章 北美和南美肺部疾病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太肺部疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲肺部疾病治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Bridge Biotherapeutics 宣布独立资料监测委员会对特发性肺纤维化 BBT-877 2a 期研究给予积极建议
    • 百时美施贵宝宣布美国FDA 授予临床实验LPA1 拮抗剂用于治疗进行性肺纤维化的突破性疗法
    • 随着气喘资金筹措的加速推进，Aeolus Bio 斥资 2.45 亿美元启动
    • Avalin 筹集 1.75 亿美元资金用于开发 IPF 吸入器
    • Lupin 与 Mark Cuban 和慢性阻塞性肺病基金会 (COPD Foundation) 合作，扩大美国慢性阻塞性肺病 (COPD) 治疗的可及性
    • Apollo Therapeutics 筹集 2.265 亿美元用于研究型药物开发
    • Viatris 与 Quindeva 合作，宣布推出 Breina（Budesonide和Formoterol福莫特罗二水合物）吸入气雾剂，这是 FDA核准的Symbicort非专利药，用于气喘和慢性阻塞性肺病患者
    • 美国FDA核准辉瑞疫苗「ABRYSVO」用于预防老年人呼吸道融合病毒（RSV）（RSV）
    • TFF 和 NIEHS 合作开发治疗呼吸道疾病的粉末製剂
    • 美国FDA核准葛兰素史克老年人呼吸道融合病毒（RSV）（RSV）疫苗“Alexi”
    • Astra Zeneca推出新型气喘治疗药物“Air Supra”
    • C4XD 与Astra Zeneca签署 4.02 亿美元协议，开发呼吸系统疾病治疗药物

第15章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-4316E4E893EF

[198 Pages Report] The Pulmonary Drugs Market size was estimated at USD 79.35 billion in 2023 and expected to reach USD 86.14 billion in 2024, at a CAGR 8.03% to reach USD 136.27 billion by 2030.

The pulmonary drugs market encompasses a wide range of therapeutic solutions specifically designed for the prevention, diagnosis, and treatment of respiratory diseases. Pulmonary drugs are primarily used in treating various respiratory conditions such as pneumonia, tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergic rhinitis, and other pulmonary ailments. The rising prevalence of pulmonary diseases and government initiatives to promote disease treatment have increased the need for pulmonary drugs. The improvements in reimbursement policies and favorable government approvals for pulmonary drugs also contribute to market growth. However, incidents of product recalls may limit the adoption of pulmonary drugs. The limitations associated with improper drug delivery and the development of drug resistance are also expected to create challenges in the adoption of pulmonary drugs. Moreover, The development of new biologics & targeted drugs for pulmonary disease treatment and advancements in inhaled drug delivery therapies are expected to create potential growth opportunities in the market.

KEY MARKET STATISTICS
Base Year [2023] USD 79.35 billion
Estimated Year [2024] USD 86.14 billion
Forecast Year [2030] USD 136.27 billion
CAGR (%) 8.03%

Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases

Anticholinergic agents are a class of drugs that block the action of acetylcholine, a neurotransmitter responsible for transmitting impulses in the airways. These medications help reduce bronchoconstriction and airway secretions, making them useful for treating chronic obstructive pulmonary disease (COPD) and asthma. Anti-leukotrienes are medications that combat inflammation in the respiratory system by blocking the effects of leukotrienes, which are chemicals involved in immune responses leading to airway constriction and mucus production. They are used primarily to treat asthma, especially in patients who do not respond well to traditional treatments such as inhaled corticosteroids or beta-2 agonists. Antihistamines work by inhibiting histamine, a chemical mediator released during allergic reactions, thereby reducing allergy symptoms such as sneezing, itching, and nasal congestion. Antihistamines can be beneficial in treating asthma and chronic rhinitis associated with allergies; however, it is primarily intended for pulmonary conditions. Beta-2 agonists are pulmonary drugs that stimulate beta-2 adrenergic receptors on bronchial smooth muscle cells, causing relaxation and bronchodilation, which is essential for managing asthma and COPD symptoms. Combination drugs contain two or more different classes of medications to enhance efficacy while minimizing side effects. They are often prescribed when single-agent therapies do not provide adequate symptom control. Monoclonal antibodies are biological drugs engineered to target specific cellular pathways involved in inflammatory and immune-mediated airway diseases, such as severe asthma. Corticosteroids, both oral and inhaled, are potent anti-inflammatory agents used to treat various pulmonary disorders such as asthma and COPD.

Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis

Allergic rhinitis is an inflammatory condition that impacts the nasal passages due to exposure to allergens, including pollen, dust mites, or animal dander. The most commonly used medications for managing this condition include antihistamines, leukotriene receptor antagonists, and intranasal corticosteroids. Asthma is a chronic inflammatory respiratory disease portraying airway obstruction and bronchospasm. Depending on the severity and individual patient needs, asthma management can involve short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), or biologics. Chronic obstructive pulmonary disease (COPD) is a lung disease involving chronic bronchitis and emphysema that results in airflow obstruction. Cystic fibrosis, a genetic disorder, causes the accumulation of thick mucus in the lungs, causing chronic infections and respiratory failure. The primary treatment approach involves targeting the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein with modulators and managing symptoms using bronchodilators, antibiotics, and mucolytics. Pulmonary arterial hypertension (PAH) is a rare, severe disorder leading to high blood pressure in the arteries supplying blood to the lungs. The main classes of drugs utilized to treat PAH include endothelin receptor antagonists (ERAs), prostacyclin analogs or agonists, soluble guanylate cyclase stimulators (sGCS), and phosphodiesterase type 5 inhibitors (PDE-5i).

Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management

Prescription drugs are medications that require a prescription from a licensed healthcare professional before they can be dispensed to patients. These medications undergo rigorous testing and regulatory processes to ensure safety and efficacy before being approved by governing agencies such as the Food & Drug Administration (FDA) or the European Medicines Agency (EMA). Prescription pulmonary drugs offer targeted therapies with advanced mechanisms of action designed to address the underlying causes of respiratory diseases. Generic drugs are bioequivalent to branded drugs in dosage form, strength, route of administration, quality, performance characteristics, and intended use. These drugs enter the market after the patent expiration of their branded counterparts and are typically priced lower than the original products. The cost-effectiveness is a primary factor driving the preference for generic drugs among healthcare providers and patients who require long-term treatments or have limited financial resources.

Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers

Hospital pharmacies are an essential distribution channel for pulmonary drugs, primarily due to their strategic location within healthcare facilities. This enables healthcare professionals to have immediate access to life-saving medications for patients with chronic and acute respiratory disorders. Online pharmacies have emerged as a convenient and cost-effective platform for purchasing pulmonary drugs. They offer advantages such as doorstep delivery, privacy, discounts, and ease of access to medications without needing a physical visit to a pharmacy store. Retail pharmacies constitute a significant distribution channel for pulmonary drugs, owing to their widespread presence and ease of access for patients.

End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals

In the homecare segment, patients with chronic respiratory diseases, including asthma, tuberculosis, and chronic obstructive pulmonary disease (COPD) require regular medication and management. Hospitals serve as critical centers for the treatment of acute exacerbations and severe cases of respiratory disorders. Specialty clinics cater to patients with specific respiratory conditions, including cystic fibrosis, interstitial lung diseases, and pulmonary arterial hypertension (PAH).

Regional Insights

The Americas region has a highly developed infrastructure for manufacturing of pulmonary drugs due to the presence of major market players in the area. In major countries such as the United States, Canada, and Brazil, respiratory diseases such as Chronic Obstructive Pulmonary Disease, Tuberculosis, and Asthma are prevalent among both children and adults, increasing the need for pulmonary drugs. EMEA countries, including Germany, France, Italy, Spain, and others, also have a high prevalence of respiratory disorders owing to the growing aging population, contributing to the market growth in the region. Middle-East countries such as Saudi Arabia and the UAE have invested heavily in health infrastructure improvements to address this public health concern. The Asian region is witnessing market growth due to increasing government investments in major countries such as China, India, and Japan. The market players in the region concentrate on producing affordable generics for pulmonary conditions and investing in the development of new drugs domestically.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pulmonary Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pulmonary Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pulmonary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Chiesi Farmaceutici S.p.A, Cipla Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Grifols, S.A., Icosavax, Inc., Johnson & Johnson Services, Inc., Lung Therapeutics Inc., Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Verona Pharma PLC, Vertex Pharmaceuticals Incorporated, Viatris Inc., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Pulmonary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Anti-Cholinergic Agents
    • Anti-Leukotrienes
    • Antihistamines
    • Beta-2 Agonists
    • Combination Drugs
    • Monoclonal Antibodies
    • Oral & Inhaled Corticosteroids
  • Indication
    • Allergic Rhinitis
    • Asthma
    • Chronic Obstructive Pulmonary Disease
    • Cystic Fibrosis
    • Pulmonary Arterial Hypertension
  • Drug Type
    • Generic Drugs
    • Prescription Drugs
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End-User
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pulmonary Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pulmonary Drugs Market?

3. What are the technology trends and regulatory frameworks in the Pulmonary Drugs Market?

4. What is the market share of the leading vendors in the Pulmonary Drugs Market?

5. Which modes and strategic moves are suitable for entering the Pulmonary Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
      • 5.1.1.2. Improvements in reimbursements and favorable government approvals for pulmonary drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Increasing recall of drugs used for pulmonary conditions
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of new biologics and targeted drugs for pulmonary disease treatment
      • 5.1.3.2. Advancements in inhaled drug delivery therapies and technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations associated with improper drug delivery and development of drug resistance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
    • 5.2.2. Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
    • 5.2.3. Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
    • 5.2.4. Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
    • 5.2.5. End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
  • 5.3. Market Trend Analysis
    • 5.3.1. Significant growth in the Americas due to rising respiratory disease prevalence and the presence of major market players developing innovative pulmonary drugs for disease management.
    • 5.3.2. Well-established space for collaborative production of innovative pulmonary drugs in the Asia-Pacific substantially backed by the government's financial support for drug commercialization
    • 5.3.3. Improving healthcare infrastructure and government support emphasize research and development to meet the pulmonary drug requirement in EMEA
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Pulmonary Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Cholinergic Agents
  • 6.3. Anti-Leukotrienes
  • 6.4. Antihistamines
  • 6.5. Beta-2 Agonists
  • 6.6. Combination Drugs
  • 6.7. Monoclonal Antibodies
  • 6.8. Oral & Inhaled Corticosteroids

7. Pulmonary Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Allergic Rhinitis
  • 7.3. Asthma
  • 7.4. Chronic Obstructive Pulmonary Disease
  • 7.5. Cystic Fibrosis
  • 7.6. Pulmonary Arterial Hypertension

8. Pulmonary Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Generic Drugs
  • 8.3. Prescription Drugs

9. Pulmonary Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Pulmonary Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Homecare
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Pulmonary Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Pulmonary Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Pulmonary Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
    • 14.3.2. Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
    • 14.3.3. Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates
    • 14.3.4. Avalyn Raises USD 175 Million in Funding to Develop Inhaled IPF Drugs
    • 14.3.5. Lupin Partners With Mark Cuban and COPD Foundation to Expand Access to COPD Medication in the US
    • 14.3.6. Apollo Therapeutics Raises USD 226.5 million to Develop Medicines Based on Uni Research
    • 14.3.7. Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
    • 14.3.8. U.S. FDA Approves ABRYSVO, Pfizer's Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
    • 14.3.9. TFF and NIEHS Partner to Develop Powder Formulations for Respiratory Diseases
    • 14.3.10. US FDA Approves GSK's Arexvy, a Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
    • 14.3.11. AstraZeneca Launches New Asthma Medication Called Airsupra
    • 14.3.12. C4XD and AstraZeneca Enter USD 402 million Deal to Develop Respiratory Disease Therapy

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PULMONARY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. PULMONARY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PULMONARY DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 333. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 334. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 336. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 338. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 339. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 342. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 343. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 344. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 345. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 346. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 347. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 348. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 349. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 352. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 353. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 354. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 355. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 356. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 357. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 358. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 359. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 360. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 361. NORWAY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)

TABLE